Combination chemotherapy with CHOP regimen in treatment naïve patients elicited an ORR of 65%Denileukin difitox monotherapy in R/R PTCL with CD25-positivity (defined as CD25+ expression >10%) attained an ORR of 61.5%; in the population without CD25-positivity ORR was 45.5% This evidence concerns the gene IL2RA and mature T-cell and NK-cell non-Hodgkin lymphoma.